Opus Genetics, Inc. (IRD)
NASDAQ: IRD · Real-Time Price · USD
1.880
+0.030 (1.62%)
At close: Nov 14, 2025, 4:00 PM EST
1.850
-0.030 (-1.60%)
After-hours: Nov 14, 2025, 6:23 PM EST
Opus Genetics Stock Forecast
Stock Price Forecast
The 5 analysts that cover Opus Genetics stock have a consensus rating of "Strong Buy" and an average price target of $7.20, which forecasts a 282.98% increase in the stock price over the next year. The lowest target is $5.00 and the highest is $9.00.
Price Target: $7.20 (+282.98%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Opus Genetics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 4 | 4 |
| Buy | 0 | 0 | 0 | 0 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $9 | Strong Buy | Maintains | $9 | +378.72% | Nov 13, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $9 | Strong Buy | Maintains | $9 | +378.72% | Nov 7, 2025 |
| Wedbush | Wedbush | Buy Initiates $8 | Buy | Initiates | $8 | +325.53% | Oct 29, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Initiates $9 | Strong Buy | Initiates | $9 | +378.72% | Oct 16, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +325.53% | Jun 27, 2025 |
Financial Forecast
Revenue This Year
14.12M
from 10.99M
Increased by 28.48%
Revenue Next Year
20.65M
from 14.12M
Increased by 46.20%
EPS This Year
-0.56
from -2.15
EPS Next Year
-0.41
from -0.56
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 16.0M | 31.5M | |||
| Avg | 14.1M | 20.6M | |||
| Low | 12.0M | 9.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 45.9% | 123.1% | |||
| Avg | 28.5% | 46.2% | |||
| Low | 9.2% | -30.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.51 | -0.32 | |
| Avg | -0.56 | -0.41 | |
| Low | -0.63 | -0.53 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.